Leerink Partnrs Issues Optimistic Forecast for ALNY Earnings

Key Points

• Leerink Partnrs has increased its FY2026 earnings per share (EPS) estimate for Alnylam Pharmaceuticals to $6.73 from $6.62, reflecting an optimistic outlook for the biopharmaceutical company.
• Alnylam reported a quarterly profit of $0.32 EPS, exceeding analyst estimates of a loss, while revenue surged to $773.69 million, significantly above the consensus estimate of $633.54 million.
• The stock has received strong ratings from multiple research firms, with a consensus price target increase leading to a current rating of "Moderate Buy" based on twenty-four buy ratings.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) - Equities researchers at Leerink Partnrs boosted their FY2026 earnings per share (EPS) estimates for shares of Alnylam Pharmaceuticals in a report released on Tuesday, October 14th. Leerink Partnrs analyst M. Foroohar now anticipates that the biopharmaceutical company will post earnings of $6.73 per share for the year, up from their previous forecast of $6.62. The consensus estimate for Alnylam Pharmaceuticals' current full-year earnings is ($1.70) per share. Leerink Partnrs also issued estimates for Alnylam Pharmaceuticals' FY2027 earnings at $11.70 EPS.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.86. The firm had revenue of $773.69 million during the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The company's quarterly revenue was up 17.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS.

A number of other research firms have also commented on ALNY. BMO Capital Markets increased their price objective on Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the company an "outperform" rating in a research note on Friday, September 5th. Chardan Capital increased their price objective on Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Stifel Nicolaus increased their price objective on Alnylam Pharmaceuticals from $441.00 to $495.00 and gave the company a "buy" rating in a research note on Monday, October 6th. Morgan Stanley raised their price target on Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the stock an "equal weight" rating in a research note on Monday, October 6th. Finally, The Goldman Sachs Group raised their price target on Alnylam Pharmaceuticals from $504.00 to $566.00 and gave the stock a "buy" rating in a research note on Tuesday, September 16th. Twenty-four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $457.08.

Alnylam Pharmaceuticals Stock Up 0.9%

ALNY opened at $469.36 on Wednesday. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10. The firm has a market cap of $61.52 billion, a P/E ratio of -190.02 and a beta of 0.36. Alnylam Pharmaceuticals has a 52 week low of $205.87 and a 52 week high of $484.21. The business's fifty day simple moving average is $453.28 and its 200 day simple moving average is $348.35.

Insider Buying and Selling

In related news, EVP Jeffrey V. Poulton sold 3,821 shares of the firm's stock in a transaction dated Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $1,727,283.05. Following the sale, the executive vice president directly owned 54,052 shares in the company, valued at approximately $24,434,206.60. This trade represents a 6.60% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Yvonne Greenstreet sold 8,924 shares of the firm's stock in a transaction dated Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $4,034,094.20. Following the sale, the chief executive officer owned 65,409 shares in the company, valued at approximately $29,568,138.45. The trade was a 12.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 98,144 shares of company stock worth $44,160,261. Corporate insiders own 1.20% of the company's stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 13,297,139 shares of the biopharmaceutical company's stock valued at $4,336,064,000 after buying an additional 240,534 shares during the period. T. Rowe Price Investment Management Inc. increased its holdings in Alnylam Pharmaceuticals by 0.8% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company's stock worth $1,192,988,000 after purchasing an additional 33,696 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Alnylam Pharmaceuticals by 5.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company's stock worth $946,466,000 after purchasing an additional 185,783 shares during the last quarter. Geode Capital Management LLC increased its holdings in Alnylam Pharmaceuticals by 3.3% during the 2nd quarter. Geode Capital Management LLC now owns 2,398,770 shares of the biopharmaceutical company's stock worth $779,857,000 after purchasing an additional 75,936 shares during the last quarter. Finally, Orbis Allan Gray Ltd increased its holdings in Alnylam Pharmaceuticals by 29.8% during the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company's stock worth $691,771,000 after purchasing an additional 486,489 shares during the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.